Corona Remedies Limited Q3FY26 Earnings Call Transcript Released Under Regulation 30
Corona Remedies Limited released the transcript of its Q3FY26 earnings conference call held on February 03, 2026, revealing strong financial performance with 15% revenue growth to Rs. 342 crores and 24% PAT growth. The company emerged as the fastest growing pharmaceutical company among top 30 in India with 18.90% growth versus IPM's 9.60%, advancing from 30th to 28th rank while maintaining guidance of 15% revenue and 20% PAT growth.
*this image is generated using AI for illustrative purposes only.
Corona Remedies Limited has released the transcript of its earnings conference call for the third quarter and nine months ended December 31, 2025, held on February 03, 2026, in compliance with SEBI regulations.
Earnings Call Transcript Release
The company formally communicated the availability of the earnings conference call transcript to stock exchanges on February 10, 2026. The call was conducted on February 03, 2026 at 04:00 p.m. (IST) and was hosted by IIFL Capital Services Limited.
| Parameter: | Details |
|---|---|
| Call Date: | February 03, 2026 |
| Time: | 04:00 p.m. (IST) |
| Host: | IIFL Capital Services Limited |
| Transcript Release: | February 10, 2026 |
| Regulatory Compliance: | SEBI (LODR) Regulations, 2015 |
The transcript has been made available on the company's website at www.coronaremedies.com and communicated to both BSE Limited (Scrip Code: 544644) and National Stock Exchange of India Limited (Symbol: CORONA).
Q3FY26 Financial Performance Highlights
During the earnings call, the management presented strong financial results for the quarter and nine-month period. The company demonstrated robust growth across key financial metrics.
| Metric: | Q3 FY26 | Q3 FY25 | Growth (%) |
|---|---|---|---|
| Revenue: | Rs. 342 crores | Rs. 298 crores | 15% |
| EBITDA: | Rs. 83 crores | Rs. 69 crores | 20% |
| EBITDA Margin: | 24.30% | 23.30% | +100 bps |
| Adjusted PAT: | Rs. 56 crores | Rs. 45 crores | 24% |
For the nine-month period, revenue reached Rs. 1,050 crores compared to Rs. 903 crores in the previous year, reflecting 16% growth. EBITDA grew by 25% to Rs. 231 crores with margin improvement of 140 basis points to 22%.
Market Performance and Strategic Updates
Corona Remedies emerged as the fastest growing pharmaceutical company among the top 30 pharma companies in India for Q3 FY26, achieving 18.90% growth compared to the Indian Pharmaceutical Market growth of 9.60%. This performance resulted in the company advancing from 30th to 28th rank in the IPM.
| Achievement: | Details |
|---|---|
| IPM Growth Rate: | 9.60% |
| Corona Growth Rate: | 18.90% |
| Market Rank: | Improved from 30th to 28th |
| Chronic Segment Contribution: | 70-72% of total revenue |
The management highlighted the successful acquisition of seven brands from Bayer in July 2025, with commercialization beginning in Q4 FY26 through the launch of Noklot Plus. The company's Gujarat facility has received EAEU GMP accreditation, enabling entry into five member countries including Russia, Kyrgyzstan, Armenia, Belarus, and Kazakhstan.
Management Participation and Future Outlook
The earnings call featured key management personnel including Managing Director and CEO Nirav Mehta, Joint Managing Director Ankur Mehta, CFO Bhavin Bhagat, and other senior executives. The management reaffirmed their annual guidance of 15% revenue growth and 20% PAT growth, supported by strong return ratios with annualized ROE at 31% and ROCE at 48% for the nine-month period.
The company maintains its focus on chronic and semi-chronic segments while expanding into new therapeutic areas including infertility and planning launches of biosimilars and GLP-1 products in the upcoming quarters.
17
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
